Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes pill boost high-altitude exercise performance?

NCT ID NCT06164665

Knowledge-focused Sponsor: United States Army Research Institute of Environmental Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether pioglitazone, a drug used for diabetes, can help the body use sugar from food during exercise at high altitude. Nine healthy men took either the drug or a placebo for five days, then exercised on a treadmill in a chamber simulating high altitude. Researchers measured how much sugar the body burned and how it affected inflammation and iron levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pioglitazone (15 mg oral daily for 5 days)
What this could lead to
If successful, this could point toward ways to improve energy use and performance during high-altitude activities.
What could go wrong
This is a very small, early-phase study with only 9 healthy men. Results may not apply to women, less fit people, or real-world high-altitude conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

9 people

The number who actually took part.

Started

Mar 2023

Finished

Jul 2023

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 39 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men aged 18 - 39 years * Born at altitudes less than 2,100 m * Physically active (exercise minimum 2 days per week) * Have supervisor approval (permanent party military and civilians) * Willing to refrain from alcohol, smokeless nicotine products and dietary supplement use during study periods * Fully vaccinated against COVID-19 Exclusion Criteria: * Born at altitudes greater than 2,100 m * Musculoskeletal injuries that compromise exercise capability * Metabolic or cardiovascular abnormalities, or gastrointestinal disorders * Taking medication that affects macronutrient metabolism and/or the ability to participate in strenuous exercise * Living in areas that are more than 1,200 m, or traveled to areas that are more than 1,200 m for five days or more within 2 months of data collection * Evidence of apnea or other sleeping disorders * Prior diagnosis of high altitude pulmonary edema or high altitude cerebral edema * Presence of asthma or respiratory tract infections * Smoking or vaping * Taking medications that interfere with oxygen delivery and transport * Anemia (HCT \<38% and HBG \<12.5 g/dL) and Sickle Cell Anemia/Trait * Blood donation within 8 weeks of beginning the study * Unwilling or unable to consume study diets or foods provided due to personal preference, dietary restrictions, and/or food allergies * Unwilling or unable to adhere to study physical restrictions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High altitude are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

altitude sickness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

High altitude

Contacts and locations

Locations

  • US Army Research Institute of Environmental Medicine

    Natick, Massachusetts, 01760, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.